Hepatitis C - Older HCV Patients Have Tough Time with Combination Therapy

Older HCV Patients Have Tough Time with Combination Therapy
MedPage Today, NJ - Jan 9, 2006... 9 - Older Japanese patients with chronic hepatitis C (HCV) infections are less likely than younger patients to tolerate combination therapy with Intron A ...

Human Genome Sciences Reports on Progress Toward Commercialization ...
MSN Money - Jan 10, 2006... was well tolerated and showed robust antiviral activity and durable dose-dependent reductions in hepatitis C viral load in 56 patients with HCV who were naive ...

Applied Biosystems Reports Fiscal 2006 Second Quarter Results
Genetic Engineering News, NY - Jan 25, 2006... Abbott Laboratories, increased 28 percent to $19.1 million from $14.9 million in the same quarter last year, due primarily to increased sales of HCV and HIV ...

Idenix Pharmaceuticals Reports Positive 4-Week Data From A Phase ...
PR Newswire (press release), NY - Jan 9, 2006... in combination with pegylated interferon during the first four weeks (arms BE) all produced proportionally greater suppression of serum HCV RNA as compared to ...

Benitec Delays IND Filing for HIV/AIDS Therapeutic Pending ...
PR Newswire (press release), NY - Jan 31, 2006... California, USA. Its lead therapeutic programs are for Hepatitis C Virus (HCV) and the Human Immunodeficiency Virus (HIV). Benitec's ...

Schering-Plough's HCV drug gets fast track
United Press International - Jan 30, 2006KENILWORTH, NJ, Jan. 30 (UPI) -- Schering-Plough said Monday the Food and Drug Administration granted fast-track status to its potential hepatitis drug. ...